Matthew Paul Kowalsky Sigilon Therapeutics, Inc. (SGTX) insider trading activity

Matthew Paul Kowalsky is CHIEF OF STAFF AND CLO of Sigilon Therapeutics, Inc.. Currently has a direct ownership of 0 shares of SGTX, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 1,925 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Matthew Paul Kowalsky Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Aug 11 2023	SELL Sale (or disposition) back to the issuer	-	1,925 Reduced 100.0%	0 Common Stock

Also insider at

ENTA

ENANTA PHARMACEUTICALS INC Healthcare

Chief Legal Officer

MPK